Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy
- 21 June 2012
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 18 (4) , 711-717
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone AcetateJournal of Clinical Oncology, 2010
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2009
- Prostate Cancer Cells Increase Androgen Sensitivity by Increase in Nuclear Androgen Receptor and Androgen Receptor Coactivators; A Possible Mechanism of Hormone-Resistance of Prostate Cancer CellsCancer Investigation, 2007
- Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspectiveCancer Science, 2006
- Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancerThe Prostate, 2005
- Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cellsAmerican Journal of Physiology-Endocrinology and Metabolism, 2005
- Mechanisms of Disease: polymorphisms of androgen regulatory genes in the development of prostate cancerNature Reviews Endocrinology, 2005
- Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer riskProstate Cancer and Prostatic Diseases, 2004
- Androgen receptor gene amplification and protein expression in hormone refractory prostate cancerBritish Journal of Cancer, 2003